Medicare billing for Spravato® (esketamine) requires accurate coding, documentation, and an understanding of how the drug and administration services are reported. G2082 and G2083 are Medicare HCPCS codes used for certain Spravato treatment sessions and include the drug and administration components under the applicable Medicare billing methodology.

G2082 is generally used to report a Spravato treatment session involving 56 mg of esketamine, while G2083 is used for a session involving 84 mg. These codes are designed to account for the treatment, including the required monitoring period following administration, when Medicare coverage and billing requirements are met.

For hospitals and eligible healthcare providers, understanding these Spravato billing codes is essential for accurate claims submission. Incorrect code selection, missing documentation, eligibility problems, or authorization issues can result in payment delays or denials.

A comprehensive Spravato billing guide should therefore cover Medicare eligibility, medical necessity, appropriate HCPCS coding, documentation, administration requirements, and claim submission procedures. Providers should also verify current Medicare guidance and payer-specific requirements because billing policies can change.

Common Spravato billing issues include incorrect coding, incomplete clinical documentation, authorization problems, inaccurate units, and claims submitted without meeting applicable coverage requirements. Regular claim audits can help identify these problems before they affect reimbursement.

A reliable Spravato reimbursement guide can help hospitals understand Medicare payment requirements and identify potential revenue leakage. Professional Spravato billing services can further support hospitals by managing eligibility verification, coding, claims submission, denial management, and payment follow-up.

Ultimately, accurate G2082 and G2083 reporting depends on following current Medicare requirements and maintaining complete documentation for each treatment encounter. Hospitals should review the latest CMS guidance before submitting Spravato claims.